Enhancing Oncology Research with Wearable DHTs
Oncology remains one of the most complex therapeutic areas and continues to be the top priority for research and development. Establishing clinical benefit is one of the most challenging and costly steps in developing new treatments for patients with cancer, and the need to include measures of symptom improvement in addition to survival and tumor-centric endpoints has been recognized by regulators.
With the advent of sensor-based digital health technologies (DHTs), we now have an unprecedented opportunity to remotely and continuously assess how study participants in cancer research function in their daily lives.
This digital endpoints guide provides information on wearable DHT adherence in oncology clinical trials, a list of digital endpoints available for oncology trials, and opportunities to advance cancer research with wearable DHTs, including:
- Supporting patient-centric oncology drug development with easy-to-use wearable technology
- Collecting previously inaccessible clinical insights for oncology trials through novel digital endpoints
- Passively examining physical activity, sleep behavior, cough and vital signs in the patient’s natural environment
- Continuously monitor patients after immunotherapy treatment, standardizing data collection and enabling earlier detection of adverse events such as cytokine release syndrome
Advancing Oncology Research with Digital Measures
Learn more about how wearables can be incorporated into oncology research for objective, sensitive, remote and continuous data capture to provide insight into quality of life and to advance immunotherapy treatments:
- Case Study: Wearable DHTs Demonstrate Meaningful Treatment Benefits for Patients with Cancer Cachexia
- The Pathway to a Digital Health Solution for Cytokine Release Syndrome Detection and Prediction
- Reimagining Oncology Clinical Trials with Digital Biomarkers
- Oncology Research and Care: Reimagining Digital Innovation